The prevalence of heart failure (HF) due to cardiac remodelling after acute myocardial
infarction (AMI) does not decrease regardless of implementation of new technologies …

Despite the enhanced knowledge of the pathophysiology of heart failure (HF), it still remains
a serious syndrome with substantial morbidity, mortality, and frequent hospitalizations …

The use of high‐sensitivity cardiac troponin (hs‐cTn) assays has become part of the daily
practice in most of the laboratories worldwide in the initial evaluation of the typical chest …

Heart failure is a growing health issue as a negative consequence of improved survival
upon myocardial infarction, unhealthy lifestyle, and the ageing of our population. The large …

The prevalence of heart failure with preserved ejection fraction (HFpEF) is steadily
increasing. Its diagnosis remains difficult and controversial and relies mostly on non …

Heart failure is a clinical syndrome with significant heterogeneity in presentation and
severity. Serial risk-stratification and prognostication can guide management decisions …

Chronic heart failure (HF) is a leading clinical and public problem posing a higher risk of
morbidity and mortality in different populations. HF appears to be in both phenotypic forms …

Biological markers have served for diagnosis, risk stratification and guided therapy of heart
failure (HF). Our knowledge regarding abilities of biomarkers to relate to several pathways of …

Статья посвящена перспективе использования новых биомаркеров для оценки тяжести
течения и прогноза хронической сердечной недостаточности (ХСН). В последние …

Heart failure (HF) is considered a leading cause of death in patients with established
cardiovascular (CV) and metabolic diseases. Although current treatment strategy has …